Prestige Consumer Healthcare (PBH) News Today

Prestige Consumer Healthcare Inc. (NYSE: PBH) shares are under pressure after a mix of negative signals that could weigh on investor sentiment.

• Positive Sentiment: Oppenheimer kept an Outperform rating on PBH, even after trimming its price target to $65 from $77, suggesting the stock still has upside from recent levels. Article source
• Neutral Sentiment: Analysts continue to see a reasonable earnings trajectory for PBH, with consensus full-year EPS at $4.54 and Zacks projecting $4.76 for FY2027 and $5.05 for FY2028.
• Neutral Sentiment: A broader analyst note highlighted upcoming Q4 earnings expectations, but no new company guidance or major business update was reported in the article. Article source
• Negative Sentiment: Zacks Research cut EPS estimates for PBH, including lowering Q2 2028 estimates to $1.24 from $1.30 and trimming FY2027/FY2028 forecasts slightly, which can signal softer long-term expectations.
• Negative Sentiment: Insider selling added to the cautious tone: VP Jeffrey Zerillo sold shares in two May 5 transactions, including 1,207 shares and 346 shares, both disclosed under a pre-arranged trading plan.
• Negative Sentiment: PBH’s latest earnings report missed expectations, with EPS of $1.14 versus $1.16 expected and revenue of $283.44 million versus $286.93 million estimated, while revenue fell 2.4% year over year.

Overall, Prestige Consumer Healthcare (PBH) is likely trading lower because analysts have nudged earnings estimates down, an insider sold shares, and the company recently posted a modest earnings miss with declining revenue. Those headwinds appear to outweigh the few constructive analyst comments.